,
6 tweets,
6 min read
Read on Twitter
WHO recommends the use of the #HIV drug #dolutegravir as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential, based on new evidence from two large clinical trials in Africa bit.ly/2JXCtN8 
#Dolutegravir is a drug to treat #HIV that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used
bit.ly/2JXCtN8
bit.ly/2JXCtN8
#Dolutegravir has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to efavirenz and nevirapine-based regimens, another #HIV treatment currently being used bit.ly/2JXCtN8
Initial studies had highlighted a possible link between #HIV drug #dolutegravir and neural tube defects (birth defects of the brain and spinal cord that cause conditions such as spina bifida) in infants born to women using the drug at the time of conception.
New data ⬇️
New data ⬇️
It remains critical to continue monitor the risk of neural tube defects associated with the #HIV drug #dolutegravir
bit.ly/2JXCtN8
bit.ly/2JXCtN8
Women and adolescent girls living with #HIV need to be able to make informed choices about their treatment
bit.ly/2JXCtN8
bit.ly/2JXCtN8
